Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
140 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - The report reviews Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) Overview 10 Therapeutics Development 11 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Stage of Development 11 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Therapy Area 12 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Indication 13 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Companies 17 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Universities/Institutes 25 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Therapeutics Assessment 27 Assessment by Monotherapy/Combination Products 27 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 34 Advenchen Laboratories, LLC 34 Amgen Inc. 35 ArQule, Inc. 36 Astellas Pharma Inc. 37 AstraZeneca Plc 38 AVEO Pharmaceuticals, Inc. 39 Batu Biologics, Inc. 40 Bayer AG 41 Boehringer Ingelheim GmbH 42 Bristol-Myers Squibb Company 43 Celon Pharma Sp. z o.o. 44 Daiichi Sankyo Company, Limited 45 Debiopharm International SA 46 Eddingpharm 47 Eisai Co., Ltd. 48 Eli Lilly and Company 50 Hutchison MediPharma Limited 51 Incyte Corporation 52 Johnson & Johnson 53 Kaken Pharmaceutical Co., Ltd. 54 Les Laboratoires Servier SAS 55 Nobelpharma Co., Ltd. 56 Novartis AG 57 Principia Biopharma Inc. 58 Vichem Chemie Research Ltd. 59 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Drug Profiles 60 ARQ-087 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 ASP-5878 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 AZD-4547 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 BAY-1163877 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 BAY-1179470 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 BMS-986036 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 CPL-043 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Debio-1347 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 DS-1123 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 E-7090 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 EDP-317 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 erdafitinib - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 GP-369 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 HMPL-453 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 INCB-54828 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 infigratinib - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 L-27 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 lenvatinib mesylate - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 lucitanib - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 LY-2874455 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 nintedanib - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 palifermin - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 PRN-1371 - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 RPT-835 - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 S-49076 - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 114 Product Description 114 Mechanism Of Action 114 R&D Progress 114 trafermin - Drug Profile 115 Product Description 115 Mechanism Of Action 115 R&D Progress 115 trafermin - Drug Profile 117 Product Description 117 Mechanism Of Action 117 R&D Progress 117 Vallovax - Drug Profile 118 Product Description 118 Mechanism Of Action 118 R&D Progress 118 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Dormant Projects 119 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Discontinued Products 122 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Featured News & Press Releases 124 Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 124 Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 124 Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 125 Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 127 Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 128 Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 130 Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 130 Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 131 Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 132 Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 133 Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 134 Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 135 Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 136 Sep 09, 2016: Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease 136 Sep 07, 2016: New long-term data demonstrates continued safety and beneficial effect of OFEV (nintedanib) for patients with IPF 137 Appendix 139 Methodology 139 Coverage 139 Secondary Research 139 Primary Research 139 Expert Panel Validation 139 Contact Us 139 Disclaimer 140
List of Tables
Number of Products under Development for, H2 2016 11 Number of Products under Development by Therapy Area, H2 2016 12 Number of Products under Development by Indication, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Early Stage Products, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Development by Companies, H2 2016 (Contd..2) 20 Products under Development by Companies, H2 2016 (Contd..3) 21 Products under Development by Companies, H2 2016 (Contd..4) 22 Products under Development by Companies, H2 2016 (Contd..5) 23 Products under Development by Companies, H2 2016 (Contd..6) 24 Number of Products under Investigation by Universities/Institutes, H2 2016 25 Products under Investigation by Universities/Institutes, H2 2016 26 Assessment by Monotherapy/Combination Products, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Pipeline by Advenchen Laboratories, LLC, H2 2016 34 Pipeline by Amgen Inc., H2 2016 35 Pipeline by ArQule, Inc., H2 2016 36 Pipeline by Astellas Pharma Inc., H2 2016 37 Pipeline by AstraZeneca Plc, H2 2016 38 Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 39 Pipeline by Batu Biologics, Inc., H2 2016 40 Pipeline by Bayer AG, H2 2016 41 Pipeline by Boehringer Ingelheim GmbH, H2 2016 42 Pipeline by Bristol-Myers Squibb Company, H2 2016 43 Pipeline by Celon Pharma Sp. z o.o., H2 2016 44 Pipeline by Daiichi Sankyo Company, Limited, H2 2016 45 Pipeline by Debiopharm International SA, H2 2016 46 Pipeline by Eddingpharm, H2 2016 47 Pipeline by Eisai Co., Ltd., H2 2016 48 Pipeline by Eli Lilly and Company, H2 2016 50 Pipeline by Hutchison MediPharma Limited, H2 2016 51 Pipeline by Incyte Corporation, H2 2016 52 Pipeline by Johnson & Johnson, H2 2016 53 Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 54 Pipeline by Les Laboratoires Servier SAS, H2 2016 55 Pipeline by Nobelpharma Co., Ltd., H2 2016 56 Pipeline by Novartis AG, H2 2016 57 Pipeline by Principia Biopharma Inc., H2 2016 58 Pipeline by Vichem Chemie Research Ltd., H2 2016 59 Dormant Projects, H2 2016 119 Dormant Projects (Contd..1), H2 2016 120 Dormant Projects (Contd..2), H2 2016 121 Discontinued Products, H2 2016 122 Discontinued Products (Contd..1), H2 2016 123
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
